Evidence map›Paper›PMID 34685631›Full record

ArticleCells2021

Oxytocin Is a Positive Allosteric Modulator of κ-Opioid Receptors but Not δ-Opioid Receptors in the G Protein Signaling Pathway.

Kanako Miyano, Yuki Yoshida, Shigeto Hirayama, Hideki Takahashi, Haruka Ono, Yoshiyuki Meguro, Sei Manabe, Akane Komatsu, Miki Nonaka, Takaaki Mizuguchi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Oxytocin and oxygen: the evolution of a solution to the 'stress of life'.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Kanako MiyanoDivision of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0003-1673-6074
Yuki YoshidaDepartment of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.
Shigeto HirayamaDepartment of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo 108-8641, Japan.ORCID 0000-0002-8293-2236
Hideki TakahashiDepartment of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo 108-8641, Japan.
Haruka OnoDepartment of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo 108-8641, Japan.
Yoshiyuki MeguroDepartment of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan.
Sei ManabeDepartment of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Akane KomatsuDepartment of Pain Control Research, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Miki NonakaDepartment of Pain Control Research, The Jikei University School of Medicine, Tokyo 105-8461, Japan.ORCID 0000-0002-6481-0294
Takaaki MizuguchiDepartment of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo 108-8641, Japan.
Hideaki FujiiDepartment of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo 108-8641, Japan.
Yoshikazu HigamiDepartment of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.
Minoru NaritaDivision of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Yasuhito UezonoDepartment of Pain Control Research, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Kitasato University · JPJikei University School of Medicine · JPTokyo University of Science · JPHoshi University · JPJichi Medical University · JPOkayama University · JP

Funding

Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science 18K07404Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science 20K07750Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science 21K06584
6 · The paper itself

Abstract

Oxytocin (OT) influences various physiological functions such as uterine contractions, maternal/social behavior, and analgesia. Opioid signaling pathways are involved in one of the analgesic mechanisms of OT. We previously showed that OT acts as a positive allosteric modulator (PAM) and enhances μ-opioid receptor (MOR) activity. In this study, which focused on other opioid receptor (OR) subtypes, we investigated whether OT influences opioid signaling pathways as a PAM for δ-OR (DOR) or κ-OR (KOR) using human embryonic kidney-293 cells expressing human DOR or KOR, respectively. The CellKey

Indexed as

Signal Transduction3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAllosteric RegulationAnimalsBinding SitesCHO CellsCricetulusCyclic AMPDiprenorphineDynorphinsElectric ImpedanceEndocytosisGTP-Binding ProteinsHEK293 CellsHumansInhibitory Concentration 503,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerCyclic AMPDiprenorphineDynorphinsGTP-Binding ProteinsOxytocinReceptors, Opioid, deltaReceptors, Opioid, kappaG-protein signaling pathwaykappa-opioid receptoropioid receptoropioidsoxytocinpositive allosteric modulator

Identifiers

PMID34685631
PMCPMC8534029
OpenAlexW3204604504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.